Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised concern about their possible association with acute hepatic failure (AHF). Data from the US FDA Adverse Event Reporting System were evaluated for signals of AHF in association with systemically administered quinolone antibiotics.
A recent study published by RSI’s Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski in the journal JGH Open: An open access journal of gastroenterology and hepatology, has shown that only ciprofloxacin displayed a marginal and significant AHF signal (PRR: 1.85 [1.21, 2.81]; EBGM: 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals.
The research team concluded that further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis.
The paper is available by clicking here.
More RSI News
RSI chairs panel session at Building the Next Generation of Canadian Infrastructure Conference
RSI chairs and presents on panel sessions for the Toronto conference, “Building the Next Generation of Canadian Infrastructure: Defining a roadmap for optimizing infrastructure planning,…
RSI Chairs Joint FAO/WHO Expert Meeting on Microbiological Risk Assessment (JEMRA)
RSI’s Dr. Emma Hartnett chaired the recent Joint FAO/WHO Expert Meeting on Microbiological Risk Assessment (JEMRA). The focus of the week-long event held March 11…
RSI partners with Engineers Canada to offer Online Workshop on the PIEVC Protocol
RSI and Engineers Canada are partnering to offer an online version of the introductory workshop on the PIEVC Protocol for infrastructure climate risk and vulnerability…
RSI contributes to newly published book on Blood Safety.
Written by experts in the field, Blood Safety: A Guide to Monitoring and Responding to Potential New Threats offers a concise yet comprehensive overview on critical issues in monitoring…